Final guidance suggests sponsors select two doses for Phase II trials with additional data requirements.
Jim Eamma
Advertisement
Executive Director and Therapeutic Strategy Lead, Oncology, at Worldwide Clinical Trials
Articles by Jim Eamma
Advertisement
Latest Updated Articles
Revolutionizing Oncology: Insights on the FDA’s Project Optimus and Dose OptimizationPublished: September 20th 2024 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer
2
Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development
3
ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen
4
Reducing Site Burden Through Better Technology Integration in Clinical Trials
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
